http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
누에나방(Bombyx moriL.) 번데기 분말 섭취와 저항성 운동훈련에 의한 에너지 대사에 미치는 영향
손진화(Son, Jin-Hwa),김이슬(Kim, Yi-Seul),김경환(Kim, Kyung-Hwan),전병덕(Jeon, Byung-Duk),권태동(Kwon, Tae-Dong) 한국체육과학회 2018 한국체육과학회지 Vol.27 No.5
The purpose of this study is to observe the silkworm pupa powder ingestion with/without resistance exercise training for energy metabolism in ICR mouse. For this purpose, four different diet groups (28 ICR mouse were grouped as the control diet group CON, the control diet resistance exercise group CORE, the silkworm pupae diet group SPD and silkworm pupa diet resistance exercise group SPRE n=7) were used. The amounts of fat mass were decreased in SPD and SPRE than CON. In addition, it was also significantly difference between the groups (p<.05). However, GLUT-2 protein expression didn’t show any significant differences between the groups. GLUT-4 protein expression showed significantly increased in SPRE group (p<.05). AMPK protein expression was also increased in SPRE compared with to CON (p<.05). FNDC5 protein expression didn’t show any significant differences between the groups. These results suggested that silkworm pupa powder ingestion and resistance exercise was affected by the energy metabolism because of high protein, linoleic acid and linolenic acid are abundant in silkworm pupa. Also, silkworm pupa can be used to improve energy metabolism in body. It is considered that the effect of edible insects can be proved as scientific basic data for the activation of edible insect industry.
손진화 ( Jinhwa Son ) 한국지급결제학회 2009 지급결제학회지 Vol.3 No.1
유가증권은 사권(재산권)이 표창되어 있는 증권으로서 그 권리의 행사에 증권을 필요로 하는 것을 말한다. 이에 대하여 전자유가증권은 재산권을 정보처리시스템에 의하여 전자문서로 작성하여 표창하고 그 권리의 이전 및 행사에 전자문서의 송신·수신을 필요로 하는 증권이라고 정의할 수 있다. 전자적 증서로서 유가증권인가 여부가 문제되는 것으로는 전자어음, 전자채권, 전자화폐의 접근매체, 선불 전자지급수단의 접근매체, 전자선하증권, 주식 등의 전자등록제도상의 전자등록부 등이다. 전자어음의 법적 성질에 관하여는 전자등록증권설과 전자유가증권설이 대립하고 있는데, 종이 어음의 전자적 상응물로서 유가증권의 일종이라고 보아야 할 것 이다. 전자채권증서의 법적 성질에 관하여는 지명채권설과 기명증권설이 대립하고 있는데, 유통성이 제한되는 기명증권의 일종으로 볼 수 있을 것이다. 전자화폐의 접근매체는 전자화폐의 유형에 따라 전자화폐카드와 디지털화폐의 전자문서로 구분할 수 있다. 전자화폐카드는 일종의 선불카드로서 법률에 의하여 특정한 목적을 위하여 금전에 갈음하여 사용되는 증서로서 그 자체 일정한 금전적 가치를 소장하고 있으므로 유가증권으로 보기는 어렵고 금권에 해당한다. 디지털화폐의 접근매체인 전자문서는 지시증권·무기명증권에 인정되는 배서 또는 교부의 방법에 의한 양도가 인정되지 아니하고, 권리자가 특정되는 경우에도 기명증권과 같이 지명채권양도의 방법으로 양도될 수 없으므로 유가증권으로 보기 어렵고, 증거증권 및 면책증권의 성질을 가진다. 선불전자지급수단의 접근매체는 실물카드 방식 또는 전자문서 방식으로 발급된다. 카드방식의 접근매체는 일종의 선불카드로서 유가증권으로 볼 수 있다. 전자문서 방식의 접근매체는 권리자가 전자문서에 특정되기는 하지만, 지명채권양도의 방법으로 양도될 수 없고, 또 지시증권·무기명증권에 인정되는 배서 또는 교부의 방법에 의한 양도도 인정되지 아니하므로 유가증권으로 보기 어렵다. 그러나 디지털상품권은 일정한 급여청구권을 정보처리시스템에 의하여 전자문서로 작성하여 표창하고 보통 무기명식으로서 그 권리의 이전 및 행사에 전자문서의 송신·수신을 필요로 하므로 유가증권으로 볼 수 있을 것이다. 전자선하증권은 발행·배서 및 권리행사가 전자어음법의 규정과 같이 규율될 예정이고 종이 선하증권과 같은 효력이 인정되므로, 종이 전자선하증권의 전자적 상응물로서 유가증권의 일종이라고 보아야 할 것이다. 전자등록제도에서 증권 없는 권리가 등록되는 전자등록부는 권리의 공시방법일뿐이며 권리의 표창성에 있어서 일반 유가증권에서의 권리와 증서의 결합의 정도에 이르지 못하고, 권리의 이전은 전자등록부의 계좌상의 대체기재에 의하고 전자문서의 송신·수신을 필요로 하지 않으며, 또 기명날인 또는 서명의 법적 효력이 있는 전자적 기법(예컨대, 전자서명)이 이용되는 것도 아니므로 유가증권으로 보기 어려울 것이다. This article is focused on the nature of electronic negotiable certificates: electronic promissory note, electronic certificate of credit, e-money card, electronic pre-payed card, electronic document of electronic pre-payed means, digital certificate of merchandise, electronic bill of lading, electronic register in electronic registration system, etc. Electronic negotiable instrument is a certificate in which property right is embodied on electronic document, and transmission and receipt of the document are required for transfer and exercise of the right. Electronic promissory note is a alternative of paper promissory note and a sort of electronic negotiable instrument. Electronic certificate of credit is a sort of electronic negotiable instrument with limited negotiability. E-money card or certificate of digital money has a money-value in itself, and therefore it is not a negotiable instrument but simply a certificate of money. Electronic pre-payed card is a sort of electronic negotiable instruments. It represents a right for delivering of a good or a service to holder of the card, requires possession of the card for excercise of the right, and transfer of the right is transferred by simply deliver of the card. However, electronic document of electronic pre-payed means as an access device is not electronic negotiable instrument. Digital certificate of merchandise is a sort of electronic negotiable instruments, and bear certificate in which transmission and receipt of the certificate are required for transfer and exercise of the right. Electronic bill of lading is a sort of electronic negotiable instruments which is regulated as the same way to electronic promissory note. Electronic register in electronic registration system is not a sort of electronic negotiable instruments. The right registered on the registry can be transferred by electronic registry on each account to related transaction, and the registry is not required for electronic signatures. The transmission and receipt of the right are not required for transfer and exercise of the right.
중등도-중증의 한국인 건선 환자에서 Ustekinumab 장기 투여에 따른 효과 및 안전성 연구
김연아 ( Yeona Kim ),배경남 ( Kyung-nam Bae ),손진화 ( Jin-hwa Son ),신기혁 ( Kihyuk Shin ),김훈수 ( Hoonsoo Kim ),고현창 ( Hyun-chang Ko ),김문범 ( Moon-bum Kim ),신봉석 ( Bong Seok Shin ),김병수 ( Byungsoo Kim ) 대한피부과학회 2022 대한피부과학회지 Vol.60 No.3
Background: Ustekinumab is a humanized monoclonal antibody targeting interleukin (IL)-12 and IL-23. Although popular, data on its long-term efficacy and safety in Korean patients with psoriasis are limited. Objective: To evaluate the long-term efficacy and safety of ustekinumab in Korean patients with psoriasis. Methods: A retrospective study in patients with moderate-to-severe psoriasis who had been treated with ustekinumab for at least 5 years was conducted. The sex, age, body mass index, medical records, previous psoriasis therapy, psoriasis area and severity index (PASI) scores, and adverse events were evaluated. Results: Twenty-five patients (median age 47.00 years) had been treated with ustekinumab for 5 years. The mean duration of psoriasis was 19.12±8.45 years, and the treatment duration with ustekinumab was 285.12±8.48 weeks. The baseline PASI was 17.52±7.38. PASI75 was achieved in 84% of the patients at week 28, and 96% of the patients maintained PASI75 during the 5-year follow-up period. Furthermore, 56% of patients reached PASI90 at 28 weeks, and 48% of patients maintained PASI90 for 5 years. No unexpected adverse events other than herpes zoster, herpes simplex, or elevated liver enzymes were reported. Conclusion: Ustekinumab demonstrated long-lasting efficacy with an acceptable safety profile in Korean patients with moderate-to-severe psoriasis. (Korean J Dermatol 2022;60(3):151∼158)
김연아 ( Yeona Kim ),하대룡 ( Dae-lyong Ha ),손진화 ( Jin-hwa Son ),신기혁 ( Kihyuk Shin ),이정수 ( Jungsoo Lee ),김훈수 ( Hoon-soo Kim ),고현창 ( Hyun-chang Ko ),김병수 ( Byung Soo Kim ),김문범 ( Moon-bum Kim ) 대한피부과학회 2020 大韓皮膚科學會誌 Vol.58 No.9
A poroma is a benign adnexal neoplasm originating from the sweat gland duct. It usually presents clinically as a soft erythematous or flesh-colored papule, plaque, or nodule on the palms and soles. In most cases, poromas manifest as a solitary lesion, but rarely, multiple lesions have been reported and are defined as poromatosis. Although the pathogenesis is unclear, poromatosis is known to be associated with actinic damage, human papillomavirus infection, radiation therapy, or polychemotherapy. Herein, we describe a 53-year-old woman who had multiple erythematous papules on her feet for a year. She had a medical history of acute lymphoblastic leukemia and had undergone polychemotherapy with stem cell transplantation. To our knowledge, poromatosis related to chemotherapy is a rare entity, and our case could be attributed to the theory that using polychemotherapy can induce poromatosis. (Korean J Dermatol 2020;58(9):617∼619)
김연아 ( Yeona Kim ),하대룡 ( Dae-lyong Ha ),손진화 ( Jin-hwa Son ),신기혁 ( Kihyuk Shin ),이정수 ( Jungsoo Lee ),김훈수 ( Hoon-soo Kim ),고현창 ( Hyun-chang Ko ),김병수 ( Byung Soo Kim ),김문범 ( Moon-bum Kim ) 대한피부과학회 2020 大韓皮膚科學會誌 Vol.58 No.9
Background: Tumoral calcinosis is characterized by the deposition of calcific masses around major joints, and it often causes significant impairment of joint function. Dermatologists sometimes encounter patients with a subcutaneous hard mass around the joint. However, there are few studies about tumoral calcinosis in the dermatologic literature, especially in Korea. Objective: The aim of this study was to determine the clinical characteristics of tumoral calcinosis. Methods: We reviewed the clinical photographs, medical records, and biopsy specimens of 11 cases of tumoral calcinosis seen at our clinic in 10 years. Results: All 11 patients were female, and the mean age at onset was 58.5 years. The mean duration of the disease was 7.1 years. Most patients (9, 81.8%) presented with an asymptomatic subcutaneous hard mass around the iliac crest. None of the patients had a family history, or abnormal serum calcium, phosphorus, and parathyroid hormone levels. All patients underwent surgery for treatment. Conclusion: Tumoral calcinosis can occur sporadically without metabolic disease. Therefore, careful history taking and biochemical work-up involving the metabolism of calcium and phosphorus should be performed. If there is no peculiarityon examination, the lesion is cured by resection. Although the sample size of this study is small, it can be inferred that the characteristics of tumoral calcinosis in Korea can be described by its predominant sex preponderance and location, that is, the female sex and the iliac crest, respectively. (Korean J Dermatol 2020;58(9):596∼600)
Brentuximab Vedotin로 치료한 CD30 양성 대세포 이행을 보인 균상식육종 1예
신준오 ( Jun-oh Shin ),배경남 ( Kyung-nam Bae ),손진화 ( Jin-hwa Son ),신기혁 ( Kihyuk Shin ),김훈수 ( Hoon-soo Kim ),고현창 ( Hyun-chang Ko ),김문범 ( Moon-bum Kim ),김병수 ( Byungsoo Kim ) 대한피부과학회 2022 대한피부과학회지 Vol.60 No.2
Large-cell transformation of mycosis fungoides (LCT-MF) is an advanced stage of primary cutaneous T-cell lymphoma with a poor prognosis. Therapeutic options for these patients are often limited, and so far, they are not promising. An 81-year-old woman with a previous history of mycosis fungoides presented with aggravation of generalized erythematous scaly patches and new onset of ulcerated tumor on the abdomen for 3 months. Histopathological examination revealed a dense dermal infiltrate composed of atypical large lymphocytes. Immunohistochemically, the tumor cells were positive for CD30 expression. A diagnosis of CD30<sup>+</sup> LCT-MF was established. She was intensively treated with methotrexate (1 month), acitretin (1 month), and rituximab with dose-modified cyclophosphamide, doxorubicin, and prednisone (1 cycle). Despite such treatments, the improvement was minimal. Subsequently, the patient was started on brentuximab vedotin, 1.8 mg/kg intravenously once every 3 weeks. She responded well to brentuximab therapy, and the skin lesions completely subsided within 12 weeks of treatment. (Korean J Dermatol 2022;60(2):106∼110)